Ameriflex Group Inc. Sells 1,640 Shares of Gilead Sciences, Inc. $GILD

Ameriflex Group Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 56.0% during the second quarter, Holdings Channel reports. The institutional investor owned 1,288 shares of the biopharmaceutical company’s stock after selling 1,640 shares during the quarter. Ameriflex Group Inc.’s holdings in Gilead Sciences were worth $139,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. Price T Rowe Associates Inc. MD grew its stake in shares of Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Gilead Sciences during the first quarter worth about $620,415,000. Kingstone Capital Partners Texas LLC purchased a new stake in shares of Gilead Sciences during the second quarter worth about $238,083,000. Los Angeles Capital Management LLC boosted its holdings in shares of Gilead Sciences by 422.6% during the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after purchasing an additional 2,040,261 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $112.69 on Friday. Gilead Sciences, Inc. has a twelve month low of $83.98 and a twelve month high of $121.83. The firm has a market cap of $139.83 billion, a P/E ratio of 22.45, a PEG ratio of 0.77 and a beta of 0.34. The company has a 50 day moving average of $114.34 and a 200 day moving average of $109.94. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same period in the previous year, the business earned $2.01 EPS. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is 62.95%.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares of the company’s stock, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 82,000 shares of company stock valued at $9,402,130. Company insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GILD. Royal Bank Of Canada increased their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a report on Friday, August 8th. Rothschild & Co Redburn increased their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, September 12th. UBS Group raised their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a report on Friday, July 25th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $117.17.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.